COST-CONSEQUENCE ANALYSIS OF SUBCUTANEOUS ABATACEPT VERSUS ADALIMUMAB IN SEROPOSITIVE, EROSIVE EARLY RHEUMATOID ARTHRITIS - BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

被引：0

作者：

Marinheiro, P. ^{[1
]}

Faustino, P. ^{[1
]}

Watanabe, S. ^{[2
]}

Lima, P. ^{[2
]}

机构：

[1] Bristol Myers Squibb, New York, NY USA

[2] IQVIA, Sao Paulo, Brazil

来源：

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2020年 / 26卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

111

引用

页码：136 / 136

页数：1

共 50 条

[41] COMPARING THE LONG-TERM IMPACT ON HEALTHCARE RESOURCES AND COSTS DUE TO SINGLE-PIECE ACRYLIC INTRAOCULAR LENS (IOL) IMPLANTATION DURING CATARACT SURGERY: A COST-CONSEQUENCE ANALYSIS FROM ITALIAN HEALTHCARE SYSTEM PERSPECTIVE
Dhariwal, M.
Bouchet, C.
VALUE IN HEALTH, 2018, 21 : S70 - S70
[42] COMPARING THE LONG-TERM COSTS ASSOCIATED WITH INTRAOCULAR LENS SELECTION AND ND:YAG LASER CAPSULOTOMY POST-CATARACT SURGERY: A COST-CONSEQUENCE ANALYSIS FROM A DUTCH HEALTHCARE SYSTEM PERSPECTIVE
Bosgra, O. J.
Busutil, R.
de Ruiter, L.
Vives, Perez C.
O'Boyle, D.
VALUE IN HEALTH, 2019, 22 : S670 - S670
[43] COST-MINIMIZATION AND BUDGET IMPACT ANALYSIS OF VENETOCLAX PLUS OBINUTUZUMAB VERSUS IBRUTINIB IN PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
Vieira, F. M.
Ribeiro, G. N.
Brito Filho, C.
Travassos, A.
VALUE IN HEALTH, 2021, 24 : S39 - S39
[44] EXPLORATORIES COST-CONSEQUENCE AND BUDGET IMPACT ANALYSIS OF SIROLIMUS-ELUTING STENT VS. ZOTAROLIMUS-ELUTING STENT FOCUSED ON THE RESTENOSIS AFTER DRUG-ELUTING STENT PLACEMENT UNDER THE PERSPECTIVE OF A BRAZILIAN PRIVATE PAYER
Baran, R.
Nasciben, V
Repsold, D.
Saggia, M. G.
VALUE IN HEALTH, 2010, 13 (03) : A162 - A162
[45] COST-MINIMIZATION ANALYSIS OF ANTI-TNF BIOLOGICS IN THE TREATMENT OF RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM (SUS) PERSPECTIVE
Scaccabarozzi, L.
VALUE IN HEALTH, 2014, 17 (03) : A229 - A229
[46] COST-MINIMIZATION OF LORLATINIB VERSUS ALECTINIB FOR FIRST LINE TREATMENT FOR TREATMENT OF ALKPOSITIVE NON-SMALL-CELL LUNG CANCER FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
Senna, T.
Alexandre, R. F.
Almeida, P.
Sebastiao, M.
Ferreira, P.
VALUE IN HEALTH, 2023, 26 (06) : S87 - S87
[47] COST PER CONSEQUENCE ANALYSIS OF ERDAFINITIB AND ANTI-PD1/PDL1 THERAPIES FOR METASTATIC UROTHELIAL CARCINOMA FGFR plus FROM THE PERSPECTIVE OF BRAZILIAN PRIVATE HEALTH SYSTEM
Souza, P.
Lancheros, J.
Souza, L.
Piedade, A.
VALUE IN HEALTH, 2020, 23 : S448 - S448
[48] COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB VERSUS CHEMOTERAPY FOR FIRST LINE TREATMENT OF NONSMALL CELL LUNG CANCER ALK plus , FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
Ferreira, P.
Senna, T.
Sebastiao, M.
Alexandre, R. F.
Almeida, P.
VALUE IN HEALTH, 2023, 26 (06) : S68 - S69
[49] PANITUMUMAB+MFOLFOX6 VERSUS BEVACIZUMAB+MFOLFOX6 AS FIRST LINE TREATMENT OF WILD-TYPE RAS METASTATIC COLORECTAL CANCER: A COST-EFFECTIVENESS ANALYSIS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
dos Santos, R. F.
Coutinho, M. B.
Haas, L.
VALUE IN HEALTH, 2015, 18 (07) : A821 - A821
[50] COST-UTILITY ANALYSIS OF TALAZOPARIB VERSUS CHEMOTHERAPY FOR PATIENTS WITH BREAST CANCER HER2-WITH MUTATION IN THE BRCA1/2 GENE FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
Almeida, P.
Sebastiao, M.
Ferreira, P.
Senna, T.
Alexandre, R. F.
VALUE IN HEALTH, 2023, 26 (06) : S274 - S274

← 1 2 3 4 5 →